Biotech | September 07, 2022
Lonza and Touchlight collaborate on end-to-end mRNA offering
Under the terms of the agreement, Lonza can now provide its customers with seamless access to Touchlight’s enzymatic DNA technology
Under the terms of the agreement, Lonza can now provide its customers with seamless access to Touchlight’s enzymatic DNA technology
The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets
This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region
Tobacco smoke increases infant morbidity and is fatal to a baby because it damages the baby’s organs
Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
Sam Samad will be departing Illumina on July 8, 2022, after serving as CFO for more than five years.
By 2025, Cipla plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry.
By 2025, the company plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry
Expansion of leading biomarker and bioanalysis company enhances bioanalytical solutions for targeted radiopharmaceuticals
Subscribe To Our Newsletter & Stay Updated
